Nastech Pharmaceutical Company Inc.
Merck Co., Inc. (MRK) Receives "Approvable" Letter From FDA On New Drug Application For ARCOXIA; FDA Tells Merck More Arcoxia Data Is Needed In Order For Pain Treatment To Gain ApprovalShire Pharmaceuticals Group PLC Release: FDA Approves FOSRENOL(R) To Reduce Phosphorus Levels In End Stage Renal Disease Patients
"We are encouraged by the timely review of the Nascobal Nasal Spray application by the New Era Arizona Coyotes FDA and we believe that we can close these issues resulting in NDA approval in the near future," said Gordon C. since 1997 for the treatment of various vitamin B 12 deficiencies and has a proven track record of safety and efficacy. Nascobal Nasal Gel is indicated for use in patients with pernicious anemia, Crohn's Disease, HIV/AIDS, and Multiple Sclerosis as well as other mal absorptive conditions that can result in Adidas Hats For Girls
vitamin B 12 deficiency. Symptoms of vitamin B 12 deficiency include fatigue, weakness, sore tongue, forgetfulness, weight loss, lack of coordination and difficulty walking. Left untreated, vitamin B 12 deficiency may lead to anemia, intestinal problems, and irreversible nerve damage. is a pharmaceutical company dedicated to the development and commercialization of innovative drug delivery technologies and products. The company's proprietary technologies focus on the delivery of small and large molecule drugs by nasal administration. These drugs include peptides, proteins and RNAi therapeutics. Intranasal drug delivery may lead to greater drug efficacy, speed of action, safety, and patient compliance. Nastech has patent applications directed to the treatment of diabetes and other metabolic diseases. The company also has published patent applications directed to intranasal delivery of acetylcholine esterase inhibitors for treatment of Alzheimer's disease and other neurological diseases. Nastech is developing a diverse product portfolio across multiple therapeutic areas, including products targeted for the treatment of obesity, sexual dysfunction, pain management, and osteoporosis. Factors that could cause actual results to differ materially from those in forward looking statements include, but Nike Cap Black Womens
Maxim Pharmaceuticals, Inc. (MAXM) To Close Treatment Protocol And Withdraw NDA For Advanced Malignant MelanomaRoche (RHHBY) And Pharmasset, Inc. Join Forces To Develop New Generation Of Hepatitis C Nike Hat Pink
1 Receives 2 Approvable Letter For NascobalR Nasal Spr
Remaining items to be completed for product approval are an FDA inspection of a supplier's B 12 raw material manufacturing facility and finalization of the product labeling. There were no FDA requirements for additional work related to manufacturing, preclinical, or clinical studies.
are not limited to: (i) the ability of Nastech to obtain additional funding; (ii) the ability of Nastech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) Nastech's and/or a partner's ability to successfully complete product research and development, including pre clinical and clinical studies and commercialization; (iv) Nastech's and/or a partner's ability to obtain required governmental approvals; and (v) Nastech's and/or a partner's ability to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward looking statements are contained in Nastech's most recent periodic reports on Form 10 K and Form 10 Q that are filed with the Securities and Exchange Commission. Nastech assumes no obligation to update and supplement forward looking statements that become untrue because of subsequent events.
BOTHELL, Wash., Nov. 1 /PRNewswire FirstCall/ Nastech Pharmaceutical Company Inc. Food and Drug Administration (FDA) on Nascobal(R) (Cyanocobalamin, USP) Nasal Spray for the treatment of vitamin B 12 deficiency. Nascobal Nasal Spray was developed by Nastech as an alternative to Nascobal Nasal Gel and worldwide marketing rights to both products were divested to Questcor Pharmaceuticals, Inc. in June 2003. Nastech will manufacture the product for Questcor following final approval by the FDA under terms of a supply agreement with Questcor.
New Era Snapbacks Black
Hermes Belt 32mm Vs 42mm
New York Giants Hat With Ball On Top
Versace Belt Silver
Ny Yankees Cap Green
Nike Hats On Women
New Era Hats Store
Adidas Hat Camo
Nike Hats Girls
Hermes Belt Mens
Adidas Hat Beige
Gucci Belt No Buckle
Ny Hats Men
Hermes Belt Black And Brown Reversible